Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Quantum Biopharma Ltd. filed an amended Form 6‑K to correct an exhibit previously furnished. The company states that an incorrect version of Exhibit 99.1 accompanied its April 16, 2024 submission, and this amendment is furnished solely to provide the correct exhibit.
The amendment does not modify or update other disclosures from the original report. The corrected Exhibit 99.1 is titled “Press Release dated April 1, 2024 - FSD Pharma Announces Filing of Year-End 2023 Results.”
Quantum Biopharma Ltd. filed an amended Form 6-K to correct an administrative error in the exhibit index of a prior submission. The amendment updates the description of Exhibit 99.1 only and states it does not modify or update any other disclosures from the original report.
Exhibit 99.1 is identified as a press release dated January 29, 2024 regarding FSD Pharma board changes and corporate updates. The filing was executed on behalf of the company by Chief Financial Officer Donal Carroll.